Detection of EBV-LMP1 antibodies in sera and clinical significance in the patients with nasopharyngeal carcinoma.
- Author:
Dandan TAO
1
;
Jiejie XU
;
Renjie CHEN
;
Yuan MAO
;
Genyan LIU
;
Mingzhe QIAO
;
Xi CHEN
;
Meiping LU
;
Jingjing DING
Author Information
1. Department of Otolaryngology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antibodies, Viral;
blood;
Carcinoma;
Case-Control Studies;
Enzyme-Linked Immunosorbent Assay;
Female;
Herpesvirus 4, Human;
immunology;
Humans;
Male;
Middle Aged;
Nasopharyngeal Carcinoma;
Nasopharyngeal Neoplasms;
blood;
pathology;
Viral Matrix Proteins;
immunology;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2011;25(9):401-405
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the levels of Epstein-Barr virus (EBV) latent membrane protein 1 Antibodies (LMP1-Ab) in nasopharyngeal carcinoma (NPC)sera and discuss the clinical significance of this test in diagnosis, prognosis, and immune-targeted therapy of NPC.
METHOD:Enzyme-linked immunosorbent assay (ELISA) and Western blot method were used to detect the LMP1-Ab levels in 61 NPC sera, 30 nasopharyngitis sera, and 55 normal sera. The relationship between the LMP1-Ab level and clinical and pathological features of NPC was analyzed.
RESULT:ELISA test showed that LMP1 antibodies level was significantly higher in nasopharyngeal carcinoma group than those in nasopharyngitis group and in healthy group and there were statistical significances (all P<0.05). In SNPC group, the LMP1-Ab level was not related to the pathological grade and cervical lymph node metastases (P>0.05). Western blot test revealed that the expression of LMP1 antibodies was higher in NPC sera than in nasopharyngitis sera and in normal sera.
CONCLUSION:LMP1-Ab level was higher in nasopharyngeal carcinoma group than in nasopharyngitis group and in normal group. Therefore, LMP1 may be considered as a tumor correlated antigen to help the diagnosis and immune-targeted therapy of NPC.
